Next-generation histology at The AD/PD™ Alzheimer’s Disease and Parkinson’s Disease Conference

Translucence Biosystems participated in the AD/PD™ Alzheimer’s Disease and Parkinson’s Disease Conference, held March 17-21, 2026, in Copenhagen, Denmark. The team connected with the Alzheimer's and Parkinson's disease research communities to discuss how tissue clearing can accelerate neurodegenerative disease research. Co-Founder and CEO, Damian Wheeler, and Director of Products and Business Development, Nathaniel Guanzon, presented work that applies our whole-brain tissue clearing techniques to evaluate CNS therapeutics and disease pathology in intact tissue. The posters they presented included recent work in Parkinson’s disease, Alzheimer’s disease, and quantitative analysis of blood-brain barrier-crossing antibody therapeutics.

Together, these posters highlighted how tissue clearing is well-suited to address the limitations of traditional histology for studying neurodegenerative disease models. Our pipeline, including tissue clearing, light sheet imaging, AI-powered 3D quantification, enables comprehensive whole-brain and organ-level insights, providing information on the target engagement, biodistribution, and phenotypic efficacy of novel therapeutics for Alzheimer's disease, Parkinson's disease, and other CNS-related diseases.

Posters Presented

Poster Spotlight: Whole-brain measurement of plaques, microglia, α-synuclein, and tyrosine hydroxylase in AD and PD model mice

This work demonstrates a workflow combining tissue clearing, light sheet imaging, and automated quantification to measure disease related pathology across the intact brain. Antibodies targeting amyloid plaques, microglia, ⍺-synuclein, and tyrosine hydroxylase enable brain wide quantification of cellular and molecular features across thousands of anatomical regions in AD and PD model mice.

‍

Poster Spotlight: Brain-wide quantification of BBB-crossing antibody therapeutics in AD model mice

This poster presents a workflow for evaluating BBB crossing antibody therapeutics across the intact brain. Tissue clearing, light sheet imaging, and automated analysis enable measurement of antibody penetration, biodistribution, and target engagement at brain wide scale, supporting system level analysis of therapeutic distribution in AD model mice.

Thank you to attendees who joined us at the AD/PD™ Alzheimer’s Disease and Parkinson’s Disease Conference in Copenhagen. We look forward to supporting your research and connecting at next year's annual conference. If we spoke at the conference, and you would like to continue the conversation, please reach out to info@translucencebio.com.